8-K: Xilio Therapeutics Q3 2025: Pipeline Progress & Cash Runway

Xilio Therapeutics reported its Q3 2025 financial results and significant pipeline advancements, including promising clinical data for vilastobart and efarindodekin alfa, extending its cash runway into Q1 2027.

Summary

• Reported Q3 2025 financial results and pipeline and business updates.
• Vilastobart Phase 2 data demonstrated a 40% Objective Response Rate (ORR) in heavily pretreated MSS mCRC patients without liver metastases and high plasma tumor mutational burden (TMB).
• Efarindodekin alfa Phase 1 data showed promising monotherapy anti-tumor activity and a generally well-tolerated safety profile in patients with advanced solid tumors.
• New preclinical data for masked T cell engager programs support best-in-class potential, demonstrating efficient masking, potent anti-tumor activity, and a broad therapeutic index.
• Cash and cash equivalents were $103.8 million as of September 30, 2025, an increase from $55.3 million as of December 31, 2024.
• Collaboration and license revenue increased to $19.1 million for the quarter ended September 30, 2025, compared to $2.3 million for the same period in 2024.
• Net loss for the quarter ended September 30, 2025, was $16.3 million, compared to $14.0 million for the same period in 2024.
• Anticipates cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027.

Sentiment

Score: 8

Explanation: The company reported strong clinical progress across its pipeline, particularly with vilastobart and efarindodekin alfa, and promising preclinical data for its T cell engager programs. Financially, a significant increase in cash and collaboration revenue, along with an extended cash runway, indicates improved financial health and operational stability, despite an increased net loss due to R&D investments. The overall tone and substance suggest positive momentum and strategic execution.

Positives

• Vilastobart Phase 2 data showed a 40% ORR in heavily pretreated MSS mCRC patients without liver metastases and high plasma TMB, with a statistically significant correlation (p=0.05) between plasma TMB status and response.
• Efarindodekin alfa Phase 1 monotherapy data demonstrated promising anti-tumor activity and a generally well-tolerated safety profile at doses over 100-fold greater than the maximum tolerated dose of recombinant human IL-12.
• Achieved a $17.5 million development milestone payment under the license agreement with Gilead Sciences, Inc. for efarindodekin alfa.
• Preclinical data for masked T cell engager programs highlight potential to significantly expand the therapeutic window and demonstrate potent anti-tumor activity with reduced systemic toxicity.
• Cash and cash equivalents significantly increased to $103.8 million as of September 30, 2025, from $55.3 million at December 31, 2024.
• Collaboration and license revenue for Q3 2025 was $19.1 million, a substantial increase from $2.3 million in Q3 2024.
• Anticipates cash runway into the first quarter of 2027, providing financial stability for ongoing operations and development.

Negatives

• Net loss increased to $16.3 million for the quarter ended September 30, 2025, compared to $14.0 million for the same period in 2024.
• Research & Development (R&D) expenses increased to $14.3 million for Q3 2025 from $10.8 million for Q3 2024, primarily due to increased clinical development activities, manufacturing, and personnel costs.
• General & Administrative (G&A) expenses increased to $6.7 million for Q3 2025 from $6.3 million for Q3 2024, mainly driven by professional and consulting fees.

Risks

• General market conditions and geopolitical uncertainties may impact operations.
• Risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting, or completing preclinical studies and clinical trials, and the timing and results of such studies.
• Potential for delays in any current or planned preclinical studies or clinical trials or the development of product candidates.
• Ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates.
• Ability to advance multiple early-stage masked T cell engager programs successfully.
• Initial, preliminary, interim, or retrospective preclinical or clinical data may not be replicated in or predictive of future preclinical or clinical data or results.
• Ability to successfully demonstrate the safety and efficacy of product candidates and gain regulatory approval on a timely basis, if at all.
• Results from preclinical studies or clinical trials for product candidates may not support further development.
• Actions of regulatory agencies may affect the initiation, timing, and progress of current or future clinical trials.
• Ability to obtain, maintain, and enforce patent and other intellectual property protection for current or future product candidates.
• Need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules.
• Impact of international trade policies on business, including U.S. and China trade policies.
• Ability to maintain collaboration or partnership agreements with AbbVie, Gilead, and Roche.

Future Outlook

Xilio Therapeutics plans to submit an Investigational New Drug (IND) application for XTX501 in mid-2026 and advance at least two masked T cell engager programs into IND-enabling studies with IND submissions planned for 2027. The company anticipates nominating development candidates for its CLDN18.2 program in Q4 2025 and STEAP1 program in H1 2026. Based on current operating plans, the company expects its cash and cash equivalents, together with the $17.5 million development milestone received from Gilead, to fund its operations and capital expenditure requirements into the first quarter of 2027.

Management Comments

• "As we advance our robust pipeline of innovative masked immunotherapies, we continue to provide additional validation of our proprietary masking technology and ability to deliver differentiated molecules across a wide range of targets and design formats." Ren Russo, Pharm.D., President and CEO.
• "At SITC, we presented compelling data across our clinical and preclinical programs, including data supporting the best-in-class potential of our masked T cell engager programs to meaningfully widen the therapeutic window relative to non-masked T cell engagers as well as our unique ability to incorporate co-stimulation to substantially improve the durability of T cell response." Ren Russo, Pharm.D., President and CEO.
• "For our clinical-stage programs, we continue to be encouraged by the promising data for both vilastobart and efarindodekin alfa, which have each shown differentiated clinical efficacy and safety for patients with high unmet need." Ren Russo, Pharm.D., President and CEO.
• "In particular, new data for vilastobart leveraging plasma TMB as a predictive biomarker showed a 40% response rate in patients with MSS mCRC without liver metastases, supporting the significant opportunity for vilastobart as a combination therapy." Ren Russo, Pharm.D., President and CEO.
• "As we look ahead to 2026, we are focused on execution across our clinical programs, while rapidly advancing XTX501, our bispecific PD-1/IL-2, toward a planned IND submission in mid 2026 and our masked T cell engager programs into IND-enabling studies." Ren Russo, Pharm.D., President and CEO.

Industry Context

Xilio Therapeutics operates in the highly competitive immuno-oncology space, focusing on tumor-activated, or masked, therapies designed to reduce systemic side effects by localizing anti-tumor activity within the tumor microenvironment. Their approach with masked CTLA-4 (vilastobart), IL-12 (efarindodekin alfa), and bispecific PD-1/IL-2 (XTX501) aims to improve the therapeutic index. The preclinical data for masked T cell engagers, particularly the ATACR and SEECR formats, positions them to address the systemic toxicity challenges of current T cell engagers, potentially offering a 'best-in-class' profile. The use of plasma TMB as a predictive biomarker for vilastobart in MSS mCRC highlights a growing trend in precision oncology to identify patient populations most likely to respond to therapy.

Comparison to Industry Standards

• Efarindodekin alfa demonstrated a generally well-tolerated safety profile at doses over 100-fold greater than the maximum tolerated dose of recombinant human IL-12, suggesting a significantly improved therapeutic window compared to traditional IL-12 therapies.
• Masked T cell engager programs aim to overcome the challenges associated with current, systemically active non-masked T cell engagers by significantly expanding the therapeutic window, positioning them as potential 'best-in-class' molecules.
• The 40% ORR for vilastobart in heavily pretreated MSS mCRC patients without liver metastases and high plasma TMB is a notable response rate in a difficult-to-treat patient population, where standard immunotherapies often have limited efficacy.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, extended cash runway, and potential for future partnerships and milestone payments, which could drive stock value.
• Patients: Potential for new, more effective, and better-tolerated cancer therapies, especially for difficult-to-treat conditions like MSS mCRC.
• Employees: Continued employment and potential growth opportunities as the pipeline advances.
• Partners (Gilead, AbbVie, Roche): Continued collaboration and potential for successful co-development and commercialization of therapies.
• Creditors: Improved financial stability and cash position reduce credit risk.

Next Steps

• Actively seeking a partner to develop vilastobart in combination with PD-(L)1 or PD1-VEGF in MSS CRC and other tumor types.
• Advancing XTX501 through IND-enabling studies.
• Planning to submit an IND application for XTX501 in mid-2026.
• Anticipates nominating development candidates for its CLDN18.2 program in Q4 2025.
• Anticipates nominating development candidates for its STEAP1 program in H1 2026.
• Anticipates advancing at least two masked T cell engager programs into IND-enabling studies and submitting IND applications for those programs in 2027.
• Xilio is responsible for conducting clinical development for efarindodekin alfa through the initial Phase 2 portion of the ongoing Phase 1/2 clinical trial.
• Gilead can elect to transition responsibilities for the development and commercialization of efarindodekin alfa after Xilio delivers a specified clinical data package, subject to a $75.0 million transition fee.

Key Dates

Recommendation

While Xilio Therapeutics has demonstrated significant clinical and preclinical progress, achieved a key milestone payment, and substantially improved its cash position, the company remains in a clinical-stage development phase with an increasing net loss. The positive data for vilastobart and efarindodekin alfa are encouraging, but these are still early to mid-stage results, and the company is actively seeking a partner for vilastobart, indicating a need for external funding or collaboration for further development. The extended cash runway is a positive, but the long-term success hinges on successful clinical trial outcomes, regulatory approvals, and commercialization, which carry inherent risks in biotechnology. A 'hold' recommendation reflects the positive momentum and improved financial stability while acknowledging the significant remaining development risks and the need for further validation of its pipeline.

Keywords

Xilio Therapeutics, XLO, biotechnology, immuno-oncology, cancer therapy, clinical trials, vilastobart, efarindodekin alfa, XTX501, T cell engagers, masked immunotherapies, CTLA-4, IL-12, PD-1/IL-2, mCRC, solid tumors, financial results, Q3 2025, pipeline, drug development, oncology